PharmAsia News Notable Notes: Will Rising Rupee Continue To Hold Back Retooled Indian Pharma Firms?
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - A confluence of new revenues from contract research and manufacturing services, in-license deals from multinational drug firms, vigorous efforts to discover new drugs, a slew of successful patent challenges and an upbeat outlook for generic drug demand, make leading Indian pharma companies attractive investments in a downbeat global economy, according to a 55-page report by IDFC-SSKI, the investment banking subsidiary of Mumbai-based Infrastructure Development Finance Company
You may also be interested in...
As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts
MUMBAI - A headlong fall in market valuation of large Indian drug makers over the last year is pushing their promoters to consider equity stake dilutions to repay debts or honor similar commitments. India's sixth-largest drug maker Wockhardt may see its promoter Habil Khorakiwala dilute 10 to 15 percent of his and his family's 74 percent equity in favor of private-equity players to raise about $150 million, PharmaAsia News has learned
As Market Crashes, India’s Wockhardt Is Pushed To Consider Equity Dilution To Raise Funds To Repay Debts
MUMBAI - A headlong fall in market valuation of large Indian drug makers over the last year is pushing their promoters to consider equity stake dilutions to repay debts or honor similar commitments. India's sixth-largest drug maker Wockhardt may see its promoter Habil Khorakiwala dilute 10 to 15 percent of his and his family's 74 percent equity in favor of private-equity players to raise about $150 million, PharmaAsia News has learned
Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability
NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March